2014年12月， 复旦大学附属肿瘤医院 在Oncotarget期刊上发表了一篇论文。在 发表4年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor ...

This manuscript provides a comprehensive overview of potential resistance mutations within MET Receptor Tyrosine Kinase and defines how specific mutations affect different inhibitors and modes of ...

Fibroblast growth factors (FGFs) signal through FGF receptor tyrosine kinases to regulate ... recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and ...

The non-receptor tyrosine kinase Src is important for many aspects of cell physiology. The viral src gene was the first retroviral oncogene to be identified, and its cellular counterpart was the ...

Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer improved outcomes for patients with mRCC, but they are far short of a cure. Despite the introduction of sorafenib and ...

Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, Colorado 80045, ...

Several mechanisms of resistance to erlotinib and gefitinib have been described in laboratory-based models (Figure 3).

The RTK, FGFR2 and the phosphatase, SHP2 are targeted with existing drugs ... Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that can be amplified in gastric cancer and ...

We open-source the source code and experiment dataset of a novel Real-time Kinematic positioning architecture with Enhanced Velocity Constraints (RTK-EVC) via Factor Graph Optimization in ...